The medical device maker raised its 2026 revenue projection after reporting 11% organic growth and a 34% surge in Artegraft sales.
LeMaitre Vascular revised its 2026 revenue outlook to $276.3 million, driven by 11% organic growth in Q2. The company cited a 34% increase in Artegraft sales, which now represent 21% of total revenue, alongside gains in grafts, shunts, and patches.
Organic growth in Q2 was fueled by a 7% price increase and 3% volume growth. Catheter sales declined 11%, offset by strength in other product lines. The updated forecast reflects continued momentum in key segments.
Management highlighted Artegraft’s expansion as a key growth driver, alongside broader demand for vascular devices. The outlook aligns with prior guidance adjustments based on strong quarterly performance.